Assessing Ambrx Biopharma: Insights From 7 Financial Analysts
Portfolio Pulse from Benzinga Insights
Ambrx Biopharma (NASDAQ:AMAM) has been rated by 7 analysts in the last three months, with 5 somewhat bullish and 2 indifferent ratings. The average 12-month price target is $22.43, down 8.45% from the previous $24.50. Analysts from B. Riley Securities, JMP Securities, Goldman Sachs, RBC Capital, and Cantor Fitzgerald have updated their ratings and price targets. Ambrx Biopharma is a clinical-stage biologics company with a declining revenue growth of -96.68% as of September 30, 2023, and a net margin of -43375.47%. The company's ROE is -9.33% and ROA is -8.34%, with a debt-to-equity ratio of 0.04.
January 09, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ambrx Biopharma has received mixed ratings from analysts, with a downward revision in the average price target to $22.43. The company's financials show significant revenue decline and poor profitability metrics.
The reduction in the average price target by analysts suggests a bearish outlook on the stock's future performance. The significant revenue decline and negative profitability metrics such as net margin and ROA further support a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100